- Home
- APRE vs SILO Comparison
APRE vs SILO Comparison
Compare APRE & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- SILO
- Stock Information
- Founded
- APRE 2006
- SILO 2010
- Country
- APRE United States
- SILO United States
- Employees
- APRE N/A
- SILO N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- SILO Apparel
- Sector
- APRE Health Care
- SILO Consumer Discretionary
- Exchange
- APRE Nasdaq
- SILO Nasdaq
- Market Cap
- APRE 8.3M
- SILO 7.3M
- IPO Year
- APRE 2019
- SILO N/A
- Fundamental
- Price
- APRE $1.47
- SILO $0.70
- Analyst Decision
- APRE Strong Buy
- SILO
- Analyst Count
- APRE 1
- SILO 0
- Target Price
- APRE $20.00
- SILO N/A
- AVG Volume (30 Days)
- APRE 40.4K
- SILO 3.1M
- Earning Date
- APRE 11-06-2025
- SILO 11-11-2025
- Dividend Yield
- APRE N/A
- SILO N/A
- EPS Growth
- APRE N/A
- SILO N/A
- EPS
- APRE N/A
- SILO N/A
- Revenue
- APRE $841,012.00
- SILO $72,102.00
- Revenue This Year
- APRE N/A
- SILO $1.86
- Revenue Next Year
- APRE N/A
- SILO N/A
- P/E Ratio
- APRE N/A
- SILO N/A
- Revenue Growth
- APRE N/A
- SILO N/A
- 52 Week Low
- APRE $1.37
- SILO $0.41
- 52 Week High
- APRE $5.01
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- APRE 45.12
- SILO 47.34
- Support Level
- APRE $1.46
- SILO $0.66
- Resistance Level
- APRE $1.57
- SILO $0.71
- Average True Range (ATR)
- APRE 0.08
- SILO 0.07
- MACD
- APRE 0.01
- SILO -0.01
- Stochastic Oscillator
- APRE 54.45
- SILO 6.90
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.